Welcome to our dedicated page for JanOne SEC filings (Ticker: JAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reviewing JanOne Inc.’s biotech and blockchain disclosures can feel like reading two industries at once. R&D expenses for its non-addictive PAD therapy sit beside crypto-payment revenue notes, and both shift quickly. If you have ever searched, “JanOne insider trading Form 4 transactions” or wondered why a JanOne quarterly earnings report 10-Q filing buried key trial milestones, you know the challenge.
StockTitan solves it. Our AI engine delivers JanOne SEC filings explained simply, streaming every 10-K, 10-Q, 8-K and Form 4 the moment EDGAR posts. You’ll see JanOne Form 4 insider transactions real-time, compare segments with a click, and get plain-English highlights that make understanding JanOne SEC documents with AI straightforward. Need rapid context on a surprise 8-K? Our summaries flag material crypto events, FDA feedback, or funding rounds so you act faster.
Dive deeper when strategy matters. A JanOne annual report 10-K simplified by our platform breaks out PAD development timelines, cash runway and blockchain compliance risks. A JanOne proxy statement executive compensation table becomes readable numbers tied to performance goals. Track executive stock transactions Form 4 alongside biotech trial updates to spot confidence signals. Each JanOne earnings report filing analysis links revenue swings to either drug development spending or ALT5 Sigma transaction volumes. For fast, reliable insight into JanOne 8-K material events explained without legalese, this page is where professionals start.
Bank of New York Mellon Corp. (BK) – Form 4 insider filing
Director Sandra O’Connor acquired 303.365 phantom stock units on 1 Jul 2025 through the company’s Deferred Compensation Plan for Directors. The units, valued at an implied $90.65 each (≈ $27.5 k total), will convert into BK common shares at a future distribution date. After the award, her aggregate beneficial ownership rose to 6,097.442 shares/units. No securities were sold and no derivatives were exercised or disposed of.
This is a routine, compensation-related accrual rather than an open-market purchase; as such, it has minimal immediate market impact but modestly increases management-equity alignment.
FAQ
What is the current stock price of JanOne (JAN)?
What is the market cap of JanOne (JAN)?
What is the core focus of JanOne Inc.?
How does JanOne Inc. integrate healthcare with fintech?
What is the significance of the ALT5 Sigma acquisition?
What differentiates JanOne Inc. in the market?
How does the company address the opioid crisis?
Who are the typical customers or partners of its fintech services?
What industries does JanOne Inc. operate in?
How does JanOne Inc. maintain its expertise and trustworthiness?
